The potential of lasmiditan in migraine.
Jasper MecklenburgBianca RaffaelliLars NeebMargarita Sanchez Del RioUwe ReuterPublished in: Therapeutic advances in neurological disorders (2020)
Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT1F) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on positive results of two pivotal phase III trials, which showed a significant difference to placebo in the proportion of patients achieving total migraine freedom within 2 h. More patients with lasmiditan achieved headache freedom and, in addition, freedom from the most bothersome symptom, that is, photophobia, than with placebo. Treatment-related side effects seem to be related to the rapid penetration of the drug into the brain and include dizziness, paresthesia and drowsiness, mostly of mild to moderate intensity. Interim results from an ongoing long-term phase III trial suggest a decrease in the frequency of adverse events after multiple lasmiditan use. Lasmiditan is a promising acute anti-migraine therapy, in particular for patients with cardiovascular risk factors, contraindications, or unwanted side effects to triptans.
Keyphrases
- phase iii
- open label
- clinical trial
- cardiovascular risk factors
- double blind
- phase ii
- drug administration
- drug induced
- placebo controlled
- liver failure
- end stage renal disease
- respiratory failure
- cardiovascular disease
- chronic kidney disease
- ejection fraction
- emergency department
- type diabetes
- study protocol
- newly diagnosed
- patient reported
- peritoneal dialysis
- resting state
- prognostic factors
- patient reported outcomes
- bone marrow
- loop mediated isothermal amplification